BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Association of Pulmonary Advanced Practice Providers (APAPP) - ECPv6.16.3//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://www.pulmapp.com
X-WR-CALDESC:Events for Association of Pulmonary Advanced Practice Providers (APAPP)
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/Denver
BEGIN:DAYLIGHT
TZOFFSETFROM:-0700
TZOFFSETTO:-0600
TZNAME:MDT
DTSTART:20250309T090000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0600
TZOFFSETTO:-0700
TZNAME:MST
DTSTART:20251102T080000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0700
TZOFFSETTO:-0600
TZNAME:MDT
DTSTART:20260308T090000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0600
TZOFFSETTO:-0700
TZNAME:MST
DTSTART:20261101T080000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0700
TZOFFSETTO:-0600
TZNAME:MDT
DTSTART:20270314T090000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0600
TZOFFSETTO:-0700
TZNAME:MST
DTSTART:20271107T080000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/Denver:20261203T080000
DTEND;TZID=America/Denver:20261203T173000
DTSTAMP:20261102T035938
CREATED:20260811T163100Z
LAST-MODIFIED:20260811T163100Z
UID:19575-1796284800-1796319000@www.pulmapp.com
SUMMARY:23rd Annual Update in Pulmonary Hypertension
DESCRIPTION:This live CE-accredited activity is the only New England symposium that illustrates novel pathways implicated in the pathogenesis of pulmonary vascular disorders and provides state-of-the-art therapeutic approaches to the management of pulmonary hypertension. This education is accomplished via a combination of didactic lectures\, case-based plenary and breakout discussions that feature leading experts as presenters and panelists. All presentations will be based on current evidence-based guidelines\, research\, and patient-centered outcomes. \nEducational Outcome\nThis CE activity offers new and experienced healthcare providers state-of-the-art education\, recent data\, case discussions\, and practical guidance on the optimal screening and management of patients who have or are suspected of having pulmonary hypertension. It is expected that learners will utilize this education to make more informed treatment decisions that will measurably improve patient outcomes. \nObjectives\nAfter completing this activity\, the participant should be better able to: \n\nReview clinical trial evidence on the safety and efficacy of emerging drug treatment options for PH\, as well as novel pathways under development\nEvaluate new and existing therapeutic options for ILD-PH\, as well as strategies for earlier recognition and interventions for this patient population\nUtilize an interactive\, case-based learning approach in the discussion of managing PH patients with challenging comorbidities\, such as renal disease\, cancer\, non-methamphetamine drug-induced PH\, and others\nDevelop an evidence-based management plan for pulmonary hypertension that incorporates use of imaging modalities\, risk assessment tools\, pharmacologic strategies\, and routine follow-up to optimize outcomes\nDiscuss the use of combination therapies\, transition treatment strategies\, and add-on treatments in the management of PAH\nAssess Guideline-Directed Medical Therapy for HFpEF and HFrEF and novel pathways in development\nRecognize the complexities or treatment decisions in patients with CTD-associated PAH and differences from CTD-associated ILD-PH\nExplore how to incorporate a collaborative model between patients\, families\, and healthcare providers to optimize shared decision-making and improve outcomes
URL:https://www.pulmapp.com/event/23rd-annual-update-in-pulmonary-hypertension/
CATEGORIES:Pulmonary Hypertension
ATTACH;FMTTYPE=image/png:https://www.pulmapp.com/wp-content/uploads/2026/08/hypertension.png
END:VEVENT
END:VCALENDAR